3(S)-(2-Methyl-pyrimidin-5-yl)-5-oxo-9-(3-methyl-5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid | 312261-83-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3(S)-(2-Methyl-pyrimidin-5-yl)-5-oxo-9-(3-methyl-5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid
• 英文别名: (3S)-3-(2-methylpyrimidin-5-yl)-9-(3-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-5-oxononanoic acid
• CAS: 312261-83-9
• 化学式: C₂₃H₃₀N₄O₃
• 分子量: 410.516
• InChiKey: HDRFULTXFCRTQX-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• EP1187592A4
  申请人：——

  公开号：EP1187592A4

  公开（公告）日：2002-11-06
• ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1187592A2

  公开（公告）日：2002-03-20
• US6410526B1
  申请人：——

  公开号：US6410526B1

  公开（公告）日：2002-06-25
• [EN] ALPHA V INTEGRIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE L'ALPHA V INTEGRINE
  申请人：MERCK & CO INC

  公开号：WO2000072801A2

  公开（公告）日：2000-12-07

  The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as alphaV integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alphaV beta3 and alphaV beta5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.